回盛生物(300871.SZ):打造集“原料藥+獸藥製劑+動物保健”的綜合性動保公司
格隆匯5月21日丨回盛生物(300871.SZ)在投資者互動平臺表示,公司以科技創新爲發展驅動力,縱向佈局上遊原料藥產業,橫向佈局寵物、禽類、反芻、水產等板塊,打造集“原料藥+獸藥製劑+動物保健”的綜合性動保公司。公司在銷售拓展、產品質量、技術服務、品牌形象、生產成本等方面的競爭力進一步增強。目前,公司在製劑和原料藥方面的產能佈局基本完成,經濟效應逐步呈現。2025年一季度,公司化藥製劑和原料藥兩大業務板塊繼續保持良好的發展態勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.